Synopsis
Synopsis
0
CEP/COS
0
VMF
0
FDF
0
Canada
0
South Africa
0
Listed Dossiers
0
EDQM
0
USP
0
JP
0
Others
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. (s)-2-((4-(3-fluorobenzoxy)benzyl)amino)propanamide
2. 2-(4-(3-fluorobenzyloxy)benzylamino)propionamide
3. Fbap Methanesulfonate
4. Fce 26743
5. Fce 28073
6. Fce-26743
7. Fce-28073
8. Nw-1015
9. Pnu 151774e
10. Pnu-151774e
11. Safinamide
12. Safinamide Methanesulfonate
13. Xadago
1. 202825-46-5
2. Safinamide Mesilate
3. (s)-2-((4-((3-fluorobenzyl)oxy)benzyl)amino)propanamide Methanesulfonate
4. Pnu-151774e
5. Nw-1015
6. Safinamide (mesylate)
7. Safinamide Methanesulfonate
8. Pnu 151774e
9. Safinamide Mesylate [usan]
10. Fce-28073
11. Nw 1015
12. Safinamide Methansulfonate
13. Ys90v3dtx0
14. Propanamide, 2-[[[4-[(3-fluorophenyl)methoxy]phenyl]methyl]amino]-, (2s)-, Methanesulfonate (1:1)
15. 202825-46-5 (mesylate)
16. Safinamide Mesilate (jan)
17. Safinamide Mesylate (usan)
18. Safinamide Mesilate [jan]
19. (s)-2-((4-((3-fluorobenzyl)oxy)benzyl)-amino)propanamide Methanesulfonate
20. Chembl48582
21. (s)-2-[[4-[(3-fluorobenzyl)oxy]benzyl]amino]propanamide Methanesulfonate
22. Unii-ys90v3dtx0
23. Fce-28073(r-isomer)
24. Safinamidemesylate
25. Equfina (tn)
26. Xadago (tn)
27. Safinamide Mesylate Salt
28. Emd 1195686 Mesylate
29. Mls006010740
30. Schembl1665715
31. Dtxsid80942414
32. Hms3884o17
33. Safinamide Mesylate (fce28073)
34. Amy38833
35. Bcp16018
36. Ex-a2640
37. Hy-70057a
38. Mfcd15145475
39. S1472
40. Safinamide Mesilate [who-dd]
41. Akos015902297
42. Ccg-268636
43. Safinamide Methanesulfonate [mi]
44. Safinamide Mesylate [orange Book]
45. Ac-27739
46. As-75602
47. Pnu-151774e,fce28073
48. Smr004701699
49. Safinamide Mesylate Salt, >=98% (hplc)
50. Cs-0006742
51. Sw219452-1
52. D10191
53. J-013174
54. Q27294690
55. (s)-2[4-(3-fluorobenzyloxy)benzylamino]propanamide Methanesulfonate
56. (s)-(+)-2-(4-(3-fluorobenzyloxy) Benzylamino)propanamide, Methanesulfonate
57. (s)-2-((4-((3-fluorobenzyl)oxy)benzyl)amino)propanamidemethanesulfonate
58. (s)-2-[4-(3-fluorobenzyloxy)benzylamino]propanamide Methanesulfonate
59. (2s)-2-[[4-[(3-fluorophenyl)methoxy]phenyl]methylamino]propanamide;methanesulfonic Acid
60. Propanamide, 2-(((4-((3-fluorophenyl)methoxy)phenyl)methyl)amino)-, (s)-, Monomethanesulfonate
Molecular Weight | 398.5 g/mol |
---|---|
Molecular Formula | C18H23FN2O5S |
Hydrogen Bond Donor Count | 3 |
Hydrogen Bond Acceptor Count | 7 |
Rotatable Bond Count | 7 |
Exact Mass | 398.13117117 g/mol |
Monoisotopic Mass | 398.13117117 g/mol |
Topological Polar Surface Area | 127 Ų |
Heavy Atom Count | 27 |
Formal Charge | 0 |
Complexity | 438 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 1 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
Xadago is indicated for the treatment of adult patients with idiopathic Parkinsons disease (PD) as add-on therapy to a stable dose of Levodopa (L-dopa) alone or in combination with other PD medicinal products in mid-to late-stage fluctuating patients.
N04B
Registration Number : 230MF10101
Registrant's Address : Frankfurter Strasse 250 64293 Darmstadt Germany
Initial Date of Registration : 2018-08-02
Latest Date of Registration : 2018-08-02
Registration Number : 304MF10141
Registrant's Address : Z. I. La Croix Cadeau, 49240 Avrille, France
Initial Date of Registration : 2022-10-12
Latest Date of Registration : 2023-10-04
Date of Issue : 2020-10-06
Valid Till : 2022-12-03
Written Confirmation Number : WC-0457A2
Address of the Firm : Unit-III, Sy.No 544, 545 & 546, Bhiknoor (V), Bhiknoor (M), Kamareddy (Dist), Te...
Date of Issue : 2022-09-30
Valid Till : 2025-08-04
Written Confirmation Number : WC-0127
Address of the Firm : A1/B, SIPCOT Industrial Complex, Kudikadu, Cuddalore-607 005
Registrant Name : Korea Ezai Co., Ltd.
Registration Date : 2020-06-24
Registration Number : Su140-6-ND
Manufacturer Name : Merck KGaA
Manufacturer Address : Frankfurter Straße 250 D-64293 Darmstadt, Germany
Registrant Name : Saehan Pharmaceutical Co., Ltd.
Registration Date : 2022-05-27
Registration Number : Su532-8-ND
Manufacturer Name : Optimus Drugs Private Limite...
Manufacturer Address : Sy. No. 239 & 240, Dothigudem Village, Pochampally Mandal, Yadadri-Bhuvanagiri Distri...
Registrant Name : Aging Life Science Co., Ltd.
Registration Date : 2023-03-03
Registration Number : 434-52-ND
Manufacturer Name : Solara Active Pharma Science...
Manufacturer Address : A1/B, Sipcot Industrial Complex, Kudikadu Village Cuddalore-607 005, Tamil Nadu, Indi...
Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.
NDC Package Code : 73435-012
Start Marketing Date : 2020-12-23
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (20kg/20kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 42973-301
Start Marketing Date : 2019-11-01
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 59651-492
Start Marketing Date : 2024-01-10
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (50kg/50kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 14639-2101
Start Marketing Date : 2013-06-01
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (10kg/10kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 72640-005
Start Marketing Date : 2019-03-29
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 59285-031
Start Marketing Date : 2020-07-20
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 82708-0005
Start Marketing Date : 2021-03-17
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Polpharma is a Polish CDMO of APIs and a significant European API producer, delivering products to companies worldwide.
About the Company : Polpharma API. European CDMO partner and API manufacturer since 1951. Poland-based CDMO and API producer, delivering products to pharmaceutical companies worldwide. Aiming at the c...
Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.
About the Company : Biophore, founded in 2007, has established itself as a reliable partner in the development and manufacturing of niche and complex pharmaceutical products. With 4 USFDA and EU-appro...
LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
About the Company : LGM Pharma is a global leader in sourcing hard-to-find APIs and intermediates for the pharmaceutical and biotech industries. LGM is also a full service CDMO providing formulation, ...
Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.
About the Company : Established in 2004, Metrochem API is one of the fastest-growing APIs, pellets & intermediates manufacturers. It has 6 dedicated manufacturing facilities for its 3 core product ...
About the Company : Suanfarma founded in 1993, is a B2B life science partner committed to health & innovation by developing, manufacturing, & distributing high-quality APIs for the pharmaceutical indu...
Zhejiang Hengkang Pharm Group is a dynamic pharmaceutical entity, spanning drug research, large-scale production, and global marketing.
About the Company : Established in 2004 and headquartered in Hangzhou, Hengkang established multiple factories, research and sales centers in Zhejiang, Shandong, and Henan. With facilities conforming ...
About the Company : HRV Global is a leading global manufacturer, seller & exporter of a wide range of APIs, advanced intermediates, pellets, food grade chemicals, food additives & food ingredients. It...
About the Company : Brother Enterprises Holding Co., Ltd. was founded in 1991 and is headquartered in Haining City, Zhejiang Province, China. With over 30 years of experience, Brother Enterprises has ...
About the Company : Jubilant Life Sciences Limited, is an integrated global pharmaceutical and life sciences company engaged in manufacture and supply of APIs, Solid Dosage Formulations, Radiopharmace...
About the Company : Optimus is one of the fastest-growing pharmaceutical companies with 16 years of experience in providing the best quality of API, Intermediates & Finished formulations in Global mar...
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Details:
Pharmanovia will take over rights from CSL and will be responsible for all commercial and regulatory activities of Xadago (safinamide), for adult patients with idiopathic Parkinson's disease.
Lead Product(s): Safinamide Mesylate
Therapeutic Area: Neurology Brand Name: Xadago
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Pharmanovia
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement October 07, 2024
Lead Product(s) : Safinamide Mesylate
Therapeutic Area : Neurology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Pharmanovia
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Pharmanovia Acquires Exclusive Rights to Treatment for Parkinson’s Disease
Details : Pharmanovia will take over rights from CSL and will be responsible for all commercial and regulatory activities of Xadago (safinamide), for adult patients with idiopathic Parkinson's disease.
Brand Name : Xadago
Molecule Type : Small molecule
Upfront Cash : Undisclosed
October 07, 2024
Details:
Under the agreement, Newron and Zambon have ended their plans to run a clinical trial to test Xadago (safinamide) for uncontrolled movements induced by levodopa in people with Parkinson’s disease.
Lead Product(s): Safinamide Mesylate
Therapeutic Area: Neurology Brand Name: Xadago
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Zambon Group SpA
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement March 15, 2023
Lead Product(s) : Safinamide Mesylate
Therapeutic Area : Neurology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Zambon Group SpA
Deal Size : Undisclosed
Deal Type : Agreement
Plans scrapped for Xadago Trial for Levodopa-induced Dyskinesia
Details : Under the agreement, Newron and Zambon have ended their plans to run a clinical trial to test Xadago (safinamide) for uncontrolled movements induced by levodopa in people with Parkinson’s disease.
Brand Name : Xadago
Molecule Type : Small molecule
Upfront Cash : Undisclosed
March 15, 2023
Details:
Under the agreement, Newron will sponsor the study and be responsible for Xadago (safinamide), development and execution, as well as leading on all related regulatory interactions. Newron and Zambon will evenly share the cost of the study.
Lead Product(s): Safinamide Mesylate
Therapeutic Area: Neurology Brand Name: Xadago
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Newron Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement May 12, 2021
Lead Product(s) : Safinamide Mesylate
Therapeutic Area : Neurology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Newron Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Agreement
Newron and Zambon Sign Agreement for Potentially Pivotal Study with Safinamide in Parkinson’s Di...
Details : Under the agreement, Newron will sponsor the study and be responsible for Xadago (safinamide), development and execution, as well as leading on all related regulatory interactions. Newron and Zambon will evenly share the cost of the study.
Brand Name : Xadago
Molecule Type : Small molecule
Upfront Cash : Undisclosed
May 12, 2021
Details:
Eisai will take over by transfer the manufacturing and marketing approval of Equfina from Meiji. Eisai, as the manufacturer and distributor of Equfina in Japan, will continue to provide information on the proper usage of Equfina.
Lead Product(s): Safinamide Mesylate
Therapeutic Area: Neurology Brand Name: Equfina
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Eisai
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement September 07, 2020
Lead Product(s) : Safinamide Mesylate
Therapeutic Area : Neurology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Eisai
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Eisai to Take Over Manufacturing and Marketing Approval for Equfina® 50 Mg Tablets (safinamide Me...
Details : Eisai will take over by transfer the manufacturing and marketing approval of Equfina from Meiji. Eisai, as the manufacturer and distributor of Equfina in Japan, will continue to provide information on the proper usage of Equfina.
Brand Name : Equfina
Molecule Type : Small molecule
Upfront Cash : Undisclosed
September 07, 2020
Details:
The marketing authorization application for safinamide in South Korea was submitted in July 2019, and through the approval of this application, South Korea became the first country in Asia outside of Japan to grant marketing approval for safinamide.
Lead Product(s): Safinamide Mesylate
Therapeutic Area: Neurology Brand Name: Equfina
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 25, 2020
Lead Product(s) : Safinamide Mesylate
Therapeutic Area : Neurology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Eisai’s Equfina receives South Korean marketing approval to treat Parkinson’s disease
Details : The marketing authorization application for safinamide in South Korea was submitted in July 2019, and through the approval of this application, South Korea became the first country in Asia outside of Japan to grant marketing approval for safinamide.
Brand Name : Equfina
Molecule Type : Small molecule
Upfront Cash : Not Applicable
June 25, 2020
DRUG PRODUCT COMPOSITIONS
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
ABOUT THIS PAGE
A Safinamide manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Safinamide, including repackagers and relabelers. The FDA regulates Safinamide manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Safinamide API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Safinamide manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Safinamide supplier is an individual or a company that provides Safinamide active pharmaceutical ingredient (API) or Safinamide finished formulations upon request. The Safinamide suppliers may include Safinamide API manufacturers, exporters, distributors and traders.
click here to find a list of Safinamide suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Safinamide DMF (Drug Master File) is a document detailing the whole manufacturing process of Safinamide active pharmaceutical ingredient (API) in detail. Different forms of Safinamide DMFs exist exist since differing nations have different regulations, such as Safinamide USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Safinamide DMF submitted to regulatory agencies in the US is known as a USDMF. Safinamide USDMF includes data on Safinamide's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Safinamide USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Safinamide suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Safinamide Drug Master File in Japan (Safinamide JDMF) empowers Safinamide API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Safinamide JDMF during the approval evaluation for pharmaceutical products. At the time of Safinamide JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Safinamide suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Safinamide Drug Master File in Korea (Safinamide KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Safinamide. The MFDS reviews the Safinamide KDMF as part of the drug registration process and uses the information provided in the Safinamide KDMF to evaluate the safety and efficacy of the drug.
After submitting a Safinamide KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Safinamide API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Safinamide suppliers with KDMF on PharmaCompass.
A Safinamide written confirmation (Safinamide WC) is an official document issued by a regulatory agency to a Safinamide manufacturer, verifying that the manufacturing facility of a Safinamide active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Safinamide APIs or Safinamide finished pharmaceutical products to another nation, regulatory agencies frequently require a Safinamide WC (written confirmation) as part of the regulatory process.
click here to find a list of Safinamide suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Safinamide as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Safinamide API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Safinamide as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Safinamide and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Safinamide NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Safinamide suppliers with NDC on PharmaCompass.
Safinamide Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Safinamide GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Safinamide GMP manufacturer or Safinamide GMP API supplier for your needs.
A Safinamide CoA (Certificate of Analysis) is a formal document that attests to Safinamide's compliance with Safinamide specifications and serves as a tool for batch-level quality control.
Safinamide CoA mostly includes findings from lab analyses of a specific batch. For each Safinamide CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Safinamide may be tested according to a variety of international standards, such as European Pharmacopoeia (Safinamide EP), Safinamide JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Safinamide USP).
LOOKING FOR A SUPPLIER?